Free Trial

Harmony Biosciences (HRMY) Stock Price, News & Analysis

Harmony Biosciences logo
$27.06 -0.22 (-0.81%)
As of 10:13 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Harmony Biosciences Stock (NASDAQ:HRMY)

Advanced

Key Stats

Today's Range
$26.92
$27.48
50-Day Range
$26.76
$38.05
52-Week Range
$26.26
$41.61
Volume
59,751 shs
Average Volume
696,801 shs
Market Capitalization
$1.55 billion
P/E Ratio
8.71
Dividend Yield
N/A
Price Target
$45.50
Consensus Rating
Moderate Buy

Company Overview

Harmony Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
93rd Percentile Overall Score

HRMY MarketRank™: 

Harmony Biosciences scored higher than 93% of companies evaluated by MarketBeat, and ranked 70th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Harmony Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.

  • Upside Potential

    Harmony Biosciences has a consensus price target of $45.50, representing about 66.8% upside from its current price of $27.28.

  • Amount of Analyst Coverage

    Harmony Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Harmony Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Harmony Biosciences are expected to grow by 27.98% in the coming year, from $2.43 to $3.11 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Harmony Biosciences is 8.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 235.10.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Harmony Biosciences is 8.80, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 86.80.

  • Price to Earnings Growth Ratio

    Harmony Biosciences has a PEG Ratio of 0.33. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Harmony Biosciences has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Harmony Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    8.54% of the float of Harmony Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Harmony Biosciences has a short interest ratio ("days to cover") of 6.1.
  • Change versus previous month

    Short interest in Harmony Biosciences has recently decreased by 1.85%, indicating that investor sentiment is improving.
  • Dividend Yield

    Harmony Biosciences does not currently pay a dividend.

  • Dividend Growth

    Harmony Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.54% of the float of Harmony Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Harmony Biosciences has a short interest ratio ("days to cover") of 6.1.
  • Change versus previous month

    Short interest in Harmony Biosciences has recently decreased by 1.85%, indicating that investor sentiment is improving.
  • News Sentiment

    Harmony Biosciences has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Harmony Biosciences this week, compared to 8 articles on an average week.
  • Search Interest

    31 people have searched for HRMY on MarketBeat in the last 30 days. This is an increase of 343% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Harmony Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    23.60% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Harmony Biosciences' insider trading history.
Receive HRMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HRMY Stock News Headlines

Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
Equities Analysts Set Expectations for HRMY Q3 Earnings
Mizuho Cuts Harmony Biosciences (NASDAQ:HRMY) Price Target to $35.00
See More Headlines

HRMY Stock Analysis - Frequently Asked Questions

Harmony Biosciences' stock was trading at $34.41 at the beginning of the year. Since then, HRMY stock has decreased by 20.7% and is now trading at $27.28.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) posted its quarterly earnings data on Tuesday, August, 5th. The company reported $0.68 earnings per share for the quarter, missing analysts' consensus estimates of $0.78 by $0.10. Harmony Biosciences's quarterly revenue was up 16.0% compared to the same quarter last year.
Read the conference call transcript
.

Harmony Biosciences (HRMY) raised $101 million in an initial public offering on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO.

Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Harmony Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/05/2025
Today
10/06/2025
Next Earnings (Estimated)
11/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HRMY
CIK
1802665
Fax
N/A
Employees
200
Year Founded
2017

Price Target and Rating

High Price Target
$61.00
Low Price Target
$33.00
Potential Upside/Downside
+66.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.10
Trailing P/E Ratio
8.80
Forward P/E Ratio
11.23
P/E Growth
0.33
Net Income
$145.49 million
Net Margins
23.44%
Pretax Margin
29.14%
Return on Equity
26.34%
Return on Assets
17.71%

Debt

Debt-to-Equity Ratio
0.20
Current Ratio
3.84
Quick Ratio
3.80

Sales & Book Value

Annual Sales
$714.73 million
Price / Sales
2.20
Cash Flow
$2.95 per share
Price / Cash Flow
9.26
Book Value
$11.56 per share
Price / Book
2.36

Miscellaneous

Outstanding Shares
57,530,000
Free Float
43,955,000
Market Cap
$1.57 billion
Optionable
Optionable
Beta
0.79

Social Links

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:HRMY) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners